D-cycloserine for Relapse Prevention Following Intravenous Ketamine in Treatment-resistant Depression
Status:
Unknown status
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
This is a two-stage experiment; the first stage is an open label trial in which participants
receive six intravenous (IV) treatments of ketamine. The second stage includes participants
that responded to ketamine (i.e. reduction of 25% in their symptoms of depression, as
measured by the Montgomery Asberg Depression Scale MADRS). The second stage is a
double-blind, controlled clinical trial of D-cycloserine (DCS) vs. placebo, as maintenance
treatment in patients who responded to ketamine treatment. The aim of the study is to
determine whether 8 weeks of DCS maintenance therapy will prevent relapse of depressive
symptoms following ketamine infusions